Cagrilintide has shown promising results in animal studies and clinical trials, demonstrating significant weight loss and improved glycemic control in obese patients with or without type 2 diabetes
Chronic in vivo Ipamorelin treatment stimulates body weight gain and growth hormone (GH) release in vitro in young female rats
These may include nausea, decreased appetite, vomiting, constipation, diarrhea, bloating, or abdominal discomfort
(PMID: 15531385), rats given BPC-157 0.0045 mg/lb showed significantly elevated serotonin synthesis in the substantia nigra reticulata and medial anterior olfactory nucleus following acute administration
The sandwich ELISA kit uses a biotinylated secondary antibody and Streptavidin-HRP for detection
doi:10.4103/0378-6323.179088